Evidence map›Paper›PMID 20427081›Full record

ArticleBiomaterials2010

Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro.

Albert Adam, Nicolas Montpas, David Keire, Anik Désormeaux, Nancy J Brown, François Marceau, Benjamin Westenberger

Open access · greenAbstract read
In one paragraph

Article in Biomaterials, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. In Vitro Modeling of Bradykinin-Mediated Angioedema States.Pharmaceuticals (Basel, Switzerland) · 2020
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Analysis and characterization of heparin impurities.Analytical and bioanalytical chemistry · 2011
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Albert AdamFaculty of Pharmacy, Université de Montréal, 2900, Boulevard E Montpetit, Montréal, Qc H3T 1J4, Canada. albert.adam@umontreal.ca
Nicolas Montpas
David Keire
Anik Désormeaux
Nancy J Brown
François Marceau
Benjamin Westenberger
Université de Montréal · CAUnited States Food and Drug Administration · USVanderbilt University Medical Center · US

Funding

GENES AND FIBRINOLYTIC CAPACITY OF HUMAN ENDOTHELIUMR01HL065193 · NHLBI · VANDERBILT UNIVERSITY · PI IKIZLER, TALAT ALP, PRETORIUS, MIAS · 2000 to 2012
$4.0M
Pharmacogenetics of ACE inhibitor-associated angioedema R01HL079184 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BROWN, NANCY J. · 2005 to 2014
$3.2M
RAAS, Inflammation &Post-Operative Atrial FibrillationR01HL077389 · NHLBI · VANDERBILT UNIVERSITY · PI BROWN, NANCY J. · 2005 to 2009
$2.7M
CIHR MOP-93773NHLBI NIH HHS 1-R01-HL079184NHLBI NIH HHS R01 HL065193NHLBI NIH HHS R01 HL077389NHLBI NIH HHS R01 HL079184
6 · The paper itself

Abstract

unlabelledOversulfated chondroitin sulfate (OSCS) contaminated heparin has been associated with severe anaphylactoid reaction (AR), mainly in dialysed patients. Although attributed to bradykinin (BK) released during contact system activation by OSCS, no definitive evidence exists until now for a BK release during incubation of contaminated heparin with human plasma. In this study, we investigated the kinin forming capacity of OSCS and OSCS contaminated heparin when incubated in vitro with a pool of human plasma. At 100 microg/mL, OSCS liberates BK in a profile similar but not identical to dextran sulfate, a well known activator of the plasma contact system. The results have highlighted that the quantity of BK accumulated during contact system activation depends not only on the concentration of OSCS but also on the plasma dilution and the presence of an angiotensin converting enzyme inhibitor. We demonstrate a highly significant correlation between the concentration of OSCS present in the contaminated heparin and BK released concentration. In conclusion, for the first time, we show that OSCS contaminated heparin incubated with human plasma has the capacity to liberate BK at a concentration that could explain the role of this inflammatory peptide in the pathophysiology of AR associated with OSCS contaminated heparin. DISCLAIMER: The findings and conclusions in this article have not been formally disseminated by the Food and Drug Administration and should not be construed to represent any Agency determination or policy.

Indexed as

Drug ContaminationAnaphylaxisAngiotensin-Converting Enzyme InhibitorsAnticoagulantsBradykininChondroitin SulfatesHeparinHumansPlasmaAngiotensin-Converting Enzyme InhibitorsAnticoagulantsBradykininChondroitin SulfatesHeparin

Identifiers

PMID20427081
PMCPMC2896062
OpenAlexW2009943303

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.